1 Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada; Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada; School of Pharmacy, University of Waterloo, Waterloo, Canada. Electronic address: bfarrell@bruyere.org.
2 Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada; Concordia University, Montreal, Quebec, Canada. Electronic address: james.conklin@concordia.ca.
3 Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, M5S 3M2, Toronto, Ontario, Canada; Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: lisa.dolovich@utoronto.ca.
4 Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada. Electronic address: hirving@bruyere.org.
5 Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2775 Laurel Street, V5Z 1M9, Vancouver, British Columbia, Canada. Electronic address: malcolm.maclure@ubc.ca.
6 Women's College Research Institute, 76 Grenville St., M5S 1B2, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, M5S 3M2, Toronto, Ontario, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: lisa.mccarthy@utoronto.ca.
7 HRB Centre for Primary Health Care Research, Royal College of Surgeons in Ireland, 123 St Stephen's Green, D02 YN77, Dublin, Ireland. Electronic address: frankmoriarty@rcsi.ie.
8 Bruyère Research Institute, 43 Bruyère St., K1N 5C8, Ottawa, Ontario, Canada; Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada; Department of Epidemiology and Community Medicine. University of Ottawa, Ottawa, Ontario, Canada. Electronic address: kpottie@uottawa.ca.
9 College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, R3E 0T5, Winnipeg, Manitoba, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, M5S 3M2, Toronto, Ontario, Canada. Electronic address: Lalitha.Raman-Wilms@umanitoba.ca.
10 NHMRC Cognitive Decline Partnership Centre, Kolling Institute of Medical Research, Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia; Geriatric Medicine Research, Faculty of Medicine and College of Pharmacy, Dalhousie University and Nova Scotia Health Authority, NS, Canada. Electronic address: emily.reeve@sydney.edu.au.
11 Research Unit of General Practice, Department of Public Health, University of Southern Denmark, JB Winsøwsvej 9, Odense, 5000 C, Denmark. Electronic address: wthompson@health.sdu.dk.

Deprescribing guidelines: An international symposium on development, implementation, research and health professional education.

Res Social Adm Pharm. 2019 06;15(6):780-789

Authors: Farrell B, Conklin J, Dolovich L, Irving H, Maclure M, McCarthy L, Moriarty F, Pottie K, Raman-Wilms L, Reeve E, Thompson W

Abstract

Deprescribing is a clinically important and feasible innovation that ensures medication efficacy, reduces harms, and mitigates polypharmacy. It involves reducing doses or stopping medications that are not useful, no longer needed, or which may be causing harm. It may also involve changing to a safer agent or using non-pharmacological approaches for care instead. Clinical guidelines combined with behaviour changes (of health care providers (HCPs), the public, and health care decision-makers) are needed to integrate deprescribing into routine practice. Using rigorous international standards, the Bruyère Research Institute Deprescribing Guidelines research team validated a ground-breaking deprescribing guideline methodology and developed or co-developed 5 evidence-based deprescribing guidelines. In March 2018, the team hosted an international symposium convening HCPs, researchers, public agencies, policymakers, and patient advocates in Ottawa, Ontario, Canada. This 3-day symposium aimed to facilitate knowledge exchange amongst guideline developers, users, and the public; initiate partnerships and collaborations for new deprescribing guideline recommendations and effectiveness research; and to continue work on HCP deprescribing education activities. An interprofessional planning committee developed an overall agenda, and small groups worked on session objectives and formats for different components: methods for rigorous deprescribing guideline development, implementation experiences, research/evaluation experiences and educational needs. Through a series of keynote speakers, panel discussions, and small working groups, the symposium provided a forum for participants to meet one another, learn about their different experiences with deprescribing guidelines, and develop collaborations for future initiatives. One hundred thirty participants, from 10 countries and representing over 100 institutions and organizations took part. Symposium proceedings are presented in this issue of RSAP for sharing with the wider community engaged in the care of patients with problematic polypharmacy.

PMID: 30241875 [PubMed - indexed for MEDLINE]